Nervtex’s MoDAS artificial intelligence (AI) system has become the first video-based, AI-powered medical device to win regulatory approval for assessing motor symptoms in Parkinson’s disease and other movement disorders, according to a company press release. The AI system, which analyzes motor symptoms based on video recorded on a…
Suppressing the activity of carnitine palmitoyl-transferase 1 (CPT1) — a key enzyme in the metabolism of fatty molecules — led to reductions in motor and non-motor symptoms in two mouse models of Parkinson’s disease, a new study shows. These benefits were associated with a normalization of blood sugar, or…
A small group of people with Parkinson’s disease adhered well to an experimental music-based digital therapy to treat gait problems, and reported quality of life gains, meeting the main goals of a small feasibility trial, according to its developer MedRhythms. Preliminary evidence of the trial (NCT04891107) that…
ATH434, Alterity Therapeutics’ experimental oral therapy, prevented a loss in the sense of smell — an early and common symptom of Parkinson’s disease — in a mouse model, and helped to preserve nerve cells and restore motor skills in older animals, a study showed. These findings add to those…
The American Parkinson Disease Association (APDA) will host a free, two-day virtual conference for people with Parkinson’s disease and their caregivers on February 15–16. The program is scheduled to run from 12 p.m. to 3:30 p.m. EST each day. “The APDA Virtual Parkinson’s Conference will include an…
The activity of multiple genes in the brain varies according to sex among people with Parkinson’s disease, a new study reports. These differences may contribute to discrepancies in how Parkinson’s tends to affect men and women. “While males have a higher age-adjusted disease incidence and are more frequently affected…
High-frequency stimulation of both the brain’s primary motor cortex (M1) and its dorsolateral prefrontal cortex (DLPFC) — two regions with altered activity in Parkinson’s disease — may be the optimal use of transcranial magnetic stimulation (TMS) in easing Parkinson’s motor symptoms, a meta-analysis study reported. In analyzing data from…
Researchers have developed a video-based algorithm to predict the severity of tremor in Parkinson’s disease patients based on the criteria of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The new algorithm was found to identify tremors, both resting and postural, with high accuracy — ranging from…
Suppressing the production of an enzyme called nitric oxide synthase 2 (NOS2) led to reductions in alpha-synuclein-related abnormalities and neuroinflammation in a mouse model of Parkinson’s disease, a new study reports. “Our data indicate that NOS2 may be a therapeutic target for modulating [Parkinson’s disease] in the brain,” the…
The U.S. Food and Drug Administration (FDA) has lifted its full clinical hold on IkT-148009, Inhibikase Therapeutics’ investigational oral therapy for Parkinson’s disease. The agency had placed a hold on all clinical trials of IkT-158009 in December, just a few months after Inhibikase had begun dosing Parkinson’s patients in a …
Get regular updates to your inbox.
